 SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 26, 2021 GLOBE NEWSWIRE -- TLC Nasdaq: TLC, TWO: 4152, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Zydus Healthcare Limited, part of Zydus Cadila group Zydus NSE: CADILAHC, an innovative, global pharmaceutical group that discovers, develops, manufactures and markets a broad range of healthcare therapies, today announced the signing of a license supply and commercialization agreement to commercialize AmphoTLCTM Amphotericin B Liposome for Injection 50mg in India. 